


Techcyte Reorganizes Board of Directors to Support Next Phase of Growth

OREM, UT, UNITED STATES, August 20, 2026 /EINPresswire.com/ -- Techcyte, a leader in AI-powered digital pathology, today announced the reorganization of its Board of Directors to support the company's continued growth and mission to develop the leading digital pathology platform.

Ralph Yarro, a Techcyte founder, will continue his service on the board as chairman. Continuing directors also include Karine Sellam, Vice President and Global Head of Business Development at Zoetis; Ben Cahoon, CEO of Techcyte; and Dr. Mohamed Salama, CMO at Sonic Healthcare USA and whose early work in blood cell classification helped inspire the company's founding.



Mark McNabb, Van Tuyl



Jim Rodgers, Mayo Clinic

Joining the board as new directors are [Mark McNabb](#), Head of the Private Capital Group at the Van Tuyl Family Office, and Jim Rodgers, CEO of Mayo Clinic Digital Pathology.

Jim Rodgers leads Mayo Clinic Digital Pathology, which focuses on scaling digital pathology through advancements in scanning, storage, artificial intelligence, and algorithm development. He brings extensive experience in healthcare innovation, commercialization, business development, and institutional strategy.

Commenting on his appointment, Rodgers said, "Pathology is entering an important period of transformation. I look forward to working together to bring digital pathology innovation into broader use."

Mark McNabb leads the Private Capital Group at the Van Tuyl Family Office and brings more than three decades of experience guiding complex organizations through growth and transformation. His career includes senior leadership roles at Nissan, Mercedes-Benz USA, General Motors, Maserati, and Volkswagen Group of America, as well as serving as the founding CEO of Electrify America.

On joining Techcyte's board, McNabb said, "Techcyte has a significant opportunity ahead. I look forward to helping the company build the operational foundation needed to pursue that opportunity at scale."

"Techcyte was founded on the belief that combining the knowledge of laboratory professionals and pathologists with advanced technology could meaningfully change how pathology is delivered," said Ben Cahoon, CEO of Techcyte. "Each member of this board brings a perspective that is important to advancing that mission. Together, they provide the clinical, technical, commercial, and operational experience needed to help Techcyte rapidly grow to reach profitability and deliver lasting value to laboratories and the people they serve."

The reorganized board will help Techcyte navigate the opportunities and decisions that come with expanding its platform, deepening strategic partnerships, and bringing AI-powered digital pathology to more laboratories.

###

About Techcyte

Techcyte is transforming the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab.

By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment.

Visit techcyte.com for more information.

Techcyte's anatomic and clinical pathology platform is for Research Use Only in the United States.

Troy Bankhead

Techcyte

+1 435 210-6200

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/935141003>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.